ASPAC III Acquisition (ASPC) Company Overview

Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are informed by six previous Phase 1 and Phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as PK/PD modeling — Topline data is expected first half of 2025 — Data from Phase 2 TRANQUILITY trial have the potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases. NEW YORK, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today presented a poster at the American Society of Preventive Cardiology (ASPC) Congress in Salt Lake City, Utah, detailing the rationale and design of the company's TRANQUILITY Phase 2 study examining the potential of its lead candidate, TOUR006, to reduce high-sensitivity C-reactive protein (hs-CRP), a key biomarker of residual inflammatory cardiovascular risk, in patients with chronic kidney disease (CKD) and elevated hs-CRP.